Skip to main content

Fruquintinib Side Effects

Medically reviewed by Drugs.com. Last updated on Jan 15, 2024.

Applies to fruquintinib: oral capsule.

Serious side effects of Fruquintinib

Along with its needed effects, fruquintinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fruquintinib:

More common

Less common

Rare

Incidence not known

Other side effects of Fruquintinib

Some side effects of fruquintinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to fruquintinib: oral capsule.

General

The most common adverse reactions that occurred in 20% or more patients were hypertension, palmar-plantar erythrodysesthesia (PPE), proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.[Ref]

Cardiovascular

Very common (10% or more): Hypertension (up to 61%), hemorrhage (up to 28%)

Uncommon (0.1% to 1%): Arterial thromboembolic event[Ref]

Dermatologic

Very common (10% or more): PPE (up to 49%)

Common (1% to 10%): Rash[Ref]

Endocrine

Very common (10% or more): Hypothyroidism (up to 21%)[Ref]

Gastrointestinal

Very common (10% or more): Stomatitis (up to 33%), abdominal pain (up to 29%), diarrhea (up to 25%)

Common (1% to 10%): Proctalgia, gastrointestinal hemorrhage, gastrointestinal perforation or fistula, intestinal obstruction

Frequency not reported: Vomiting[Ref]

Hematologic

Very common (10% or more): Decreased lymphocytes (up to 30%), decreased platelets (up to 30%), increased activated partial thromboplastin time (up to 21%), decreased hemoglobin (up to 23%)

Uncommon (0.1% to 1%): Thrombotic microangiopathy[Ref]

Hepatic

Very common (10% or more): Increased AST (up to 42%), increased ALT (up to 34%)

Frequency not reported: Hepatic function abnormalities, hepatic failure/encephalopathy[Ref]

Metabolic

Very common (10% or more): Anorexia (up to 21%), increased glucose (up to 43%), increased urate (up to 26%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (up to 22%), back pain (up to 15%) arthralgia (up to 13%)[Ref]

Nervous system

Uncommon (0.1% to 1%): Posterior reversible encephalopathy syndrome

Frequency not reported: Cerebral infarction[Ref]

Other

Very common (10% or more): Fatigue (up to 53%), increased triglycerides (53%), increased cholesterol (37%), decreased albumin (up to 35%), decreased sodium (up to 35%), increased alkaline phosphatase (up to 40%), decreased magnesium (up to 20%), decreased calcium (up to 25%), decreased potassium (up to 22%)

Uncommon (0.1% to 1%): Sepsis, septic shock

Frequency not reported: Multiple organ dysfunction, bacterial infection, asthenia, wound dehiscence[Ref]

Renal

Very common (10% or more): Proteinuria (up to 55%), increased creatinine (up to 87%)

Common (1% to 10%): Urinary tract infection, pneumonia[Ref]

Respiratory

Very common (10% or more): Dysphonia (up to 38%), throat pain (up to 10%)

Common (1% to 10%): Epistaxis, upper respiratory tract infection

Frequency not reported: Hemoptysis, lower respiratory infection[Ref]

References

1. Product Information. Fruzaqla (fruquintinib). Takeda Pharmaceuticals America. 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.